Conv. Plasma
Nigella Sativa

All vitamin D studies
Meta analysis
study COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Recovery 49% Improvement Relative Risk PASC 68% Hospitalization 26% unadjusted Vitamin D for COVID-19  Choi et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 257 patients in South Korea (April - December 2022) Improved recovery (p=0.002) and lower PASC (p=0.001) Choi et al., J. Korean Medical Science, Jan 2024 Favors vitamin D Favors control

Prognostic Factors for Predicting Post-COVID-19 Condition in Patients With COVID-19 in an Outpatient Setting

Choi et al., Journal of Korean Medical Science, doi:10.3346/jkms.2024.39.e23
Jan 2024  
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
*, now known with p < 0.00000000001 from 118 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 257 outpatients with mild COVID-19 in South Korea showing vitamin D deficiency (<20 ng/mL) associated with post-COVID condition and longer symptom duration.
This is the 191st of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of no recovery, 48.9% lower, HR 0.51, p = 0.002, high D levels (≥20ng/mL) 99, low D levels (<20ng/mL) 67, adjusted per study, multivariable.
risk of PASC, 68.4% lower, HR 0.32, p = 0.001, high D levels (≥20ng/mL) 99, low D levels (<20ng/mL) 67, adjusted per study, inverted to make HR<1 favor high D levels (≥20ng/mL), multivariable.
risk of hospitalization, 25.6% lower, RR 0.74, p = 0.48, high D levels (≥20ng/mL) 11 of 99 (11.1%), low D levels (<20ng/mL) 10 of 67 (14.9%), NNT 26, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Choi et al., 2 Jan 2024, retrospective, South Korea, peer-reviewed, mean age 55.7, 6 authors, study period April 2022 - December 2022. Contact:
This PaperVitamin DAll
Prognostic Factors for Predicting Post-COVID-19 Condition in Patients With COVID-19 in an Outpatient Setting
Myeong Geun Choi, Young Woong Joo, Min-Ho Kim, Sojung Park, Yune-Young Shin, MD Eun Mi Chun
Journal of Korean Medical Science, doi:10.3346/jkms.2024.39.e23
Background: Although data on post-coronavirus disease 2019 (COVID-19) conditions are extensive, the prognostic factors affecting symptom duration in non-hospitalized patients with COVID-19 are currently not well known. We aimed to investigate the various prognostic factors affecting symptom duration among outpatients with COVID-19. Methods: Data were analyzed from 257 patients who were diagnosed with mild COVID-19 and visited the 'post-COVID-19 outpatient clinic' between April and December 2022 after a mandatory isolation period. The symptom duration was measured from diagnosis to symptom resolution. Laboratory and pulmonary function test results from their first visit were collected. Results: The mean age of patients was 55.7 years, and the median symptom duration was 57 days. The development of post-COVID-19 conditions (> 12 weeks) were significantly correlated with not using antiviral drugs, leukocytosis (white blood cell > 10,000/µL), lower 25(OH)D 3 levels, forced vital capacity (FVC) < 90% predicted, and presence of dyspnea and anxiety/depression. Additionally, in multivariable Cox regression analysis, not using antiviral drugs, lower 25(OH)D 3 levels, and having dyspnea were poor prognostic factors for longer symptom duration. Particularly, vitamin D deficiency (< 20 ng/mL) and not using antivirals during the acute phase were independent poor prognostic factors for both post-COVID-19 condition and longer symptom duration. Conclusion: The non-use of antivirals, lower 25(OH)D 3 levels, leukocytosis, FVC < 90% predicted, and the presence of dyspnea and anxiety/depression symptoms could be useful prognostic factors for predicting post-COVID-19 condition in outpatients with COVID-19. We suggest that the use of antiviral agents during the acute phase and vitamin D supplements might help reduce COVID-19 symptom duration.
SUPPLEMENTARY MATERIALS Supplementary Table 1 The incidence of clinical symptoms of patients with COVID- 4 Baseline characteristics of the study population at the time of their first visit to the outpatient department according to Vit D deficiency Click here to view Supplementary Table 5 Baseline characteristics of the study population at the time of their first visit to the outpatient department according to use of antiviral agent at acute phase of COVID-19 Click here to view
Amin, Kakamad, Ahmed, Ahmed, Abdulla et al., Post COVID-19 pulmonary fibrosis; a meta-analysis study, Ann Med Surg (Lond), doi:10.1016/j.amsu.2022.103590
Aminian, Bena, Pantalone, Burguera, Association of obesity with postacute sequelae of COVID-19, Diabetes Obes Metab, doi:10.1111/dom.14454
Augustin, Schommers, Stecher, Dewald, Gieselmann et al., Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study, Lancet Reg Health Eur, doi:10.1016/j.lanepe.2021.100122
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bilezikian, Bikle, Hewison, Lazaretti-Castro, Formenti et al., Mechanisms in endocrinology: vitamin D and COVID-19, Eur J Endocrinol, doi:10.1530/EJE-20-0665
Butt, Dargham, Coyle, Yassine, Al-Khal et al., COVID-19 disease severity in persons infected with Omicron BA.1 and BA.2 sublineages and association with vaccination status, JAMA Intern Med, doi:10.1001/jamainternmed.2022.3351
Carfì, Bernabei, Landi, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19, JAMA, doi:10.1001/jama.2020.12603
Chen, Haupert, Zimmermann, Shi, Fritsche et al., Global prevalence of postcoronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review, J Infect Dis, doi:10.1093/infdis/jiac136
Daines, Zheng, Elneima, Harrison, Lone et al., Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19, ERJ Open Res, doi:10.1183/23120541.00274-2022
Daneshkhah, Agrawal, Eshein, Subramanian, Roy et al., Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients, Aging Clin Exp Res, doi:10.1007/s40520-020-01677-y
Dhawan, Gopalan, Howard, Vicente, Park et al., Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19, Lancet Respir Med, doi:10.1016/S2213-2600(20)30407-0
Dissanayake, Silva, Sumanatilleke, De Silva, Gamage et al., Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis, J Clin Endocrinol Metab, doi:10.1210/clinem/dgab892
Dror, Morozov, Daoud, Namir, Yakir et al., Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness, PLoS One, doi:10.1371/journal.pone.0263069
Fernández-De-Las-Peñas, Palacios-Ceña, Gómez-Mayordomo, Florencio, Cuadrado et al., Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis, Eur J Intern Med, doi:10.1016/j.ejim.2021.06.009
Fernández-De-Las-Peñas, Pellicer-Valero, Navarro-Pardo, Palacios-Ceña, Florencio et al., Symptoms experienced at the acute phase of SARS-CoV-2 infection as risk factor of long-term post-COVID symptoms: the LONG-COVID-EXP-CM multicenter study, Int J Infect Dis, doi:10.1016/j.ijid.2022.01.007
Gao, Piernas, Astbury, Hippisley-Cox, 'rahilly et al., Associations between bodymass index and COVID-19 severity in 6•9 million people in England: a prospective, community-based, cohort study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(21)00089-9
Gottlieb, Vaca, Paredes, Mera, Webb et al., Early remdesivir to prevent progression to severe COVID-19 in outpatients, N Engl J Med, doi:10.1056/NEJMoa2116846
Grant, Lahore, Mcdonnell, Baggerly, French et al., Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths, Nutrients, doi:10.3390/nu12040988
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe COVID-19, N Engl J Med, doi:10.1056/NEJMoa2007016
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Holick, Vitamin D deficiency, N Engl J Med, doi:10.1056/NEJMra070553
Huang, Huang, Wang, Li, Ren et al., 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study, Lancet, doi:10.1016/S0140-6736(20)32656-8
Huang, Kovalic, Graber, Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity, Emerg Infect Dis, doi:10.3201/eid2608.201160
Jung, Ha, Choe, Lee, Jo et al., Persistent symptoms after acute COVID-19 infection in Omicron era, J Korean Med Sci, doi:10.3346/jkms.2022.37.e213
Kamal, Omirah, Hussein, Saeed, Assessment and characterisation of post-COVID-19 manifestations, Int J Clin Pract, doi:10.1111/ijcp.13746
Lopez-Leon, Wegman-Ostrosky, Perelman, Sepulveda, Rebolledo et al., More than 50 long-term effects of COVID-19: a systematic review and meta-analysis, Sci Rep, doi:10.1038/s41598-021-95565-8
Macintyre, Crapo, Viegi, Johnson, Van Der Grinten et al., Standardisation of the single-breath determination of carbon monoxide uptake in the lung, Eur Respir J, doi:10.1183/09031936.05.00034905
Magnúsdóttir, Lovik, Unnarsdóttir, Mccartney, Ask et al., Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study, Lancet Public Health, doi:10.1016/S2468-2667(22)00042-1
Michelen, Manoharan, Elkheir, Cheng, Dagens et al., Characterising long COVID: a living systematic review, BMJ Glob Health, doi:10.1136/bmjgh-2021-005427
Miller, Hankinson, Brusasco, Burgos, Casaburi et al., Standardisation of spirometry, Eur Respir J, doi:10.1183/09031936.05.00034805
Munker, Veit, Barton, Mertsch, Mümmler et al., Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity, Infection, doi:10.1007/s15010-021-01669-8
Nalbandian, Sehgal, Gupta, Madhavan, Mcgroder et al., Post-acute COVID-19 syndrome, Nat Med, doi:10.1038/s41591-021-01283-z
Nielsen, Junker, Boelt, Cohen, Munger et al., Vitamin D status and severity of COVID-19, Sci Rep, doi:10.1038/s41598-022-21513-9
Oscanoa, Amado, Vidal, Laird, Ghashut et al., The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration -a metaanalysis, Adv Respir Med, doi:10.5603/ARM.a2021.0037
Pizzini, Aichner, Sahanic, Böhm, Egger et al., Impact of vitamin D deficiency on COVID-19-a prospective analysis from the CovILD registry, Nutrients, doi:10.3390/nu12092775
Renaud-Charest, Lui, Eskander, Ceban, Ho et al., Onset and frequency of depression in post-COVID-19 syndrome: a systematic review, J Psychiatr Res, doi:10.1016/j.jpsychires.2021.09.054
Song, Hui, Hull, Birring, Mcgarvey et al., Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses, Lancet Respir Med, doi:10.1016/S2213-2600(21)00125-9
Stavem, Ghanima, Olsen, Gilboe, Einvik, Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study, Thorax, doi:10.1136/thoraxjnl-2020-216377
Subramanian, Nirantharakumar, Hughes, Myles, Williams et al., Symptoms and risk factors for long COVID in non-hospitalized adults, Nat Med, doi:10.1038/s41591-022-01909-w
Sudre, Murray, Varsavsky, Graham, Penfold et al., Attributes and predictors of long COVID, Nat Med, doi:10.1038/s41591-021-01292-y
Tenforde, Kim, Lindsell, Rose, Shapiro et al., Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States, March-June 2020, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6930e1
Townsend, Dyer, Mccluskey, 'brien, Dowds et al., Investigating the relationship between vitamin D and persistent symptoms following SARS-CoV-2 infection, Nutrients, doi:10.3390/nu13072430
Tsampasian, Elghazaly, Chattopadhyay, Debski, Naing et al., Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis, JAMA Intern Med, doi:10.1001/jamainternmed.2023.0750
Ulloa, Buchan, Daneman, Brown, Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada, JAMA, doi:10.1001/jama.2022.2274
Wolter, Jassat, Walaza, Welch, Moultrie et al., Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study, Lancet, doi:10.1016/S0140-6736(22)00017-4
Yang, Luo, Gan, Chen, Li, Risk factors for predicting mortality of COVID-19 patients: a systematic review and meta-analysis, PLoS One, doi:10.1371/journal.pone.0243124
Ye, Pang, Li, Li, Liu et al., Both underweight and obesity are associated with an increased risk of coronavirus disease 2019 (COVID-19) severity, Front Nutr, doi:10.3389/fnut.2021.649422
Zhang, Bai, Yue, Qin, Zhang et al., Eight months follow-up study on pulmonary function, lung radiographic, and related physiological characteristics in COVID-19 survivors, Sci Rep, doi:10.1038/s41598-021-93191-y
Zhu, Feng, Jiang, Mi, Yang et al., Correlation between white blood cell count at admission and mortality in COVID-19 patients: a retrospective study, BMC Infect Dis, doi:10.1186/s12879-021-06277-3
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop